Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Clinical trial NCT06395103 · RECRUITING

Trial details

NCT number: NCT06395103
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B-cell Acute Lymphoblastic Leukemia Diffuse Large B-cell Lymphoma Burkitt Lymphoma Neuroblastoma Ewing Sarcoma

Start date: 2024-08-16
Primary completion: 2029-03-31
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.